clinical trial · NCT07318155
A Study of SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease
Sirius Therapeutics Co., Ltd.·phase2·recruiting·n = 104
Coronary Artery Disease (CAD)Peripheral Arterial DiseaseSRSD1070.9 % sodium chloride
brief summary
The study is a Phase 2a, randomized, double-blind, placebo-controlled, sequential cohort study to evaluate the pharmacodynamics (PD), safety and pharmacokinetics (PK) of multiple doses of SRSD107 in participants with coronary arterial disease (CAD) and/or peripheral arterial disease (PAD) with aspirin as background concomitant therapy.
started
Mar 11, 2025
primary completion
Dec 1, 2027
completion
Dec 1, 2028
last updated
Apr 29, 2026
official title
A Phase 2a Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort Study to Evaluate the Pharmacodynamics, Safety and Pharmacokinetics of Subcutaneously Administered SRSD107 in Participants With Chronic Coronary and/or Peripheral Arterial Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol